Bioventus BVS Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number at other companies

Globus MedicalGMED

——

SI-BONE, Inc.SIBN

——

Other financials

Income statement

See full

Revenue$132.1M+6.6%

Gross profit$90.8M+9.3%

Operating income$8.4M+72.8%

Net income$3.1M+218%

EPS (diluted)$0.04+200%

Balance sheet

See full

Cash & equivalents$35.8M+57.2%

Total debt$288.4M-21.2%

Total equity$188.9M+27.5%

Total assets$650.5M-5.9%

Cash flow

See full

Operating cash flow$8.9M+146%

CapEx$574.0K-30.5%

Free cash flow$8.4M+141%

Valuation

See full

Market cap$659.19M+51.7%

Enterprise value$911.76M+17.2%

P/E23.1×—

P/S1.1×+0.4×

Profitability

See full

Gross margin68.7%+1.2pp

Operating margin10%—

Net margin4.9%+3.2pp

FCF margin17.5%+13.2pp

Returns & leverage

See full

Return on equity16.9%+10.9pp

Debt / equity1.5×-0.9×

Current ratio1.7×+0.3×

Where this comes from

Reported directly by Bioventus in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.

The official record: Bioventus’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bioventus's share-based compensation arrangement by share-based payment award, options, outstanding, number.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Bioventus's share-based compensation arrangement by share-based payment award, options, outstanding, number?: Bioventus (BVS) reported share-based compensation arrangement by share-based payment award, options, outstanding, number of $5.67M in Q1 2026.
How has Bioventus's share-based compensation arrangement by share-based payment award, options, outstanding, number changed year-over-year?: Bioventus's share-based compensation arrangement by share-based payment award, options, outstanding, number increased by 12.0% year-over-year, from $5.06M to $5.67M.